Akari Taps Zealand Ex-CEO Solomon To Reboot Tick-Based Group's Prospects
Executive Summary
Struggling to restore investor confidence amid controversy, Akari has convinced former Zealand CEO David Solomon to take on the same role there and try to re-energize the NY-based biotech.
You may also be interested in...
Life after Lyxumia: Ex-Zealand CEO Solomon's next quest is to cure HIV
David Horn Solomon spent six years heading up Zealand Pharma, developer of the GLP-1 agonist Lyxumia (lixisenatide), which has travelled a bumpy road in the hands of licensing partner Sanofi. He is now CEO of Bionor Pharma, a company that is hoping to make headway with its HIV vaccine. Rather a challenge, but Dr Solomon believes the company is a clear two years ahead of the competition and with his guidance stands a real chance of being the first to tackle the 'What's next?' question in the treatment of HIV.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.